Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed, Cisplatin, and Bevacizumab Induction and Maintenance in Advanced NSCLC
NCT01004250Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Oct 2009; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01004250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01004250.